Volume 2 (2015): Issue 2

Into the future with novel emerging therapies for haemophilia

Open Access | | Creative Commons Attribution NonCommercial NoDerivatives
Dr David Perry

Abstract

Abstract

Patients with haemophilia have benefited hugely from the advances in basic science achieved over the past 50 years. The introduction of clotting factor concentrates opened the door to home treatment and the subsequent availability of plasma and then recombinant products heralded the prophylaxis era. As clinicians and patients begin to manage the introduction of longer-acting factor concentrates, there are also many novel therapies and approaches in development, many of which offer the potential to transform the lives for individuals with inherited bleeding disorders and their families.

Article

View Full Article

References

  • 1. Lane S. Haemorrhagic diathesis: successful transfusion of blood. Lancet 1940; 41(i): 185-188.
  • 2. Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci USA 1982; 79(21): 6461-4.
  • 3. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312(5992): 326-30.
  • 4. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312(5992): 330-7.
  • 5. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature 1984; 312(5992): 337-42.
  • 6. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312(5992): 342-7.
  • 7. Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369(24): 2313-23. doi: 10.1056/ NEJMoa1305074.
  • 8. Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123(3): 317-25. doi: 10.1182/ blood-2013-10-529974.
  • 9. Collins PW, Fischer K, Morfini M, et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
  • 10. Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost 2015; 13(5): 743-54. doi: 10.1111/jth.12864.
  • 11. Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015; 21(5): 492-7. doi: 10.1038/nm.3847.
  • 12. Müller J, Isermann B, Dücker C, et al. An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. Chem Biol 2009; 16(4): 442-51. doi: 10.1016/j.chembiol.2009.03.007.
  • 13. Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 2014; 124(20): 3165-71. doi: 10.1182/blood-2014-07-585737.

PDF Download

Download PDF

Open in full-page viewer

Authors